Khuri FR - Search Results

1

Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer.

Ren H, Tang X, Lee JJ, Feng L, Everett AD, Hong WK, Khuri FR, Mao L. Ren H, et al. Among authors: khuri fr. J Clin Oncol. 2004 Aug 15;22(16):3230-7. doi: 10.1200/JCO.2004.02.080. J Clin Oncol. 2004. PMID: 15310766

2

Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer.

Shin DM, Glisson BS, Khuri FR, Clifford JL, Clayman G, Benner SE, Forastiere AA, Ginsberg L, Liu D, Lee JJ, Myers J, Goepfert H, Lotan R, Hong WK, Lippman SM. Shin DM, et al. Among authors: khuri fr. J Clin Oncol. 2002 Jan 15;20(2):364-70. doi: 10.1200/JCO.2002.20.2.364. J Clin Oncol. 2002. PMID: 11786562 Clinical Trial.

3

Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation.

Soria JC, Lee HY, Lee JI, Wang L, Issa JP, Kemp BL, Liu DD, Kurie JM, Mao L, Khuri FR. Soria JC, et al. Among authors: khuri fr. Clin Cancer Res. 2002 May;8(5):1178-84. Clin Cancer Res. 2002. PMID: 12006535

4

hTERT expression is a prognostic factor of survival in patients with stage I non-small cell lung cancer.

Wang L, Soria JC, Kemp BL, Liu DD, Mao L, Khuri FR. Wang L, et al. Among authors: khuri fr. Clin Cancer Res. 2002 Sep;8(9):2883-9. Clin Cancer Res. 2002. PMID: 12231532

5

Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer.

Herbst RS, Madden TL, Tran HT, Blumenschein GR Jr, Meyers CA, Seabrooke LF, Khuri FR, Puduvalli VK, Allgood V, Fritsche HA Jr, Hinton L, Newman RA, Crane EA, Fossella FV, Dordal M, Goodin T, Hong WK. Herbst RS, et al. Among authors: khuri fr. J Clin Oncol. 2002 Nov 15;20(22):4440-7. doi: 10.1200/JCO.2002.04.006. J Clin Oncol. 2002. PMID: 12431966 Clinical Trial.

6

Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer.

Chang YS, Wang L, Liu D, Mao L, Hong WK, Khuri FR, Lee HY. Chang YS, et al. Among authors: khuri fr. Clin Cancer Res. 2002 Dec;8(12):3669-75. Clin Cancer Res. 2002. PMID: 12473575

7

Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer.

Chang YS, Kong G, Sun S, Liu D, El-Naggar AK, Khuri FR, Hong WK, Lee HY. Chang YS, et al. Among authors: khuri fr. Clin Cancer Res. 2002 Dec;8(12):3796-802. Clin Cancer Res. 2002. PMID: 12473592

8

Lack of interleukin-10 expression could predict poor outcome in patients with stage I non-small cell lung cancer.

Soria JC, Moon C, Kemp BL, Liu DD, Feng L, Tang X, Chang YS, Mao L, Khuri FR. Soria JC, et al. Among authors: khuri fr. Clin Cancer Res. 2003 May;9(5):1785-91. Clin Cancer Res. 2003. PMID: 12738735

9

Mechanisms underlying lack of insulin-like growth factor-binding protein-3 expression in non-small-cell lung cancer.

Chang YS, Wang L, Suh YA, Mao L, Karpen SJ, Khuri FR, Hong WK, Lee HY. Chang YS, et al. Among authors: khuri fr. Oncogene. 2004 Aug 26;23(39):6569-80. doi: 10.1038/sj.onc.1207882. Oncogene. 2004. PMID: 15247904

10

Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers.

Lu C, Soria JC, Tang X, Xu XC, Wang L, Mao L, Lotan R, Kemp B, Bekele BN, Feng L, Hong WK, Khuri FR. Lu C, et al. Among authors: khuri fr. J Clin Oncol. 2004 Nov 15;22(22):4575-83. doi: 10.1200/JCO.2004.01.091. J Clin Oncol. 2004. PMID: 15542809

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

479 results

Search Page